Results of a Spanish Lung Cancer Group Phase III Trial

James Metz, MD

University of Pennsylvania Cancer
Last Modified: May 12, 2001

Presenter: V. Alberola
Affiliation: Spanish Lung Cancer Group


    The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens, including a regimen without Cisplatin based therapy.

Materials and Methods:

  • This study included patients with stage IIIb and IV NSCLC.
  • Most patients were has ECOG performance status 0 or 1.
  • Patients were randomized to receive CG (n=166) vs CGV (n=176) vs GV/IV (n=175)


  • anemia and nausea/vomiting were significantly increased in the CGV regimen
  • The median survival, 1 year survival, and time to progression were not significantly different between the arms

Authors' Conclusions

  • The response rate, time to progression, and survival were the same for CG as the addition of a 3rd agent
  • The hematologic toxicity was increased in the Cisplatin containing arms
  • There was no survival differences between the regimens

Clinical/Scientific Implications:

  • The addition of a third agent to a Cisplatin containing regimen was not shown to increase the benefits for patients
  • The experimental arms in this study were not superior to the control are of CG

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

In phase III trial, the taxane drug improves survival after failure of docetaxel-based therapy

Oct 4, 2010

In phase III trial, the taxane drug improves survival after failure of docetaxel-based therapy

Gefitinib Outperforms Combo Therapy in Lung Cancer Trial

Nov 25, 2015

Patients with epidermal growth factor receptor gene mutations benefit most from gefitinib

New Treatment Option for Some With Metastatic Lung Cancer

Sep 30, 2015

Nivolumab found most effective in tumors expressing programmed death-ligand 1